Redefining FOLFIORINOX in Older Pancreatic Cancer Patients

Eligibility Criteria

• 1. Age 65 years or older
• 2. The treating physician will use their discretion when assessing if the patient is eligible for this treatment.
• 3. Patients must have newly diagnosed and previously untreated, histologically or cytologically confirmed adenocarcinoma of the pancreas, with at least one site of metastatic disease (local recurrences after surgery allowed), with lesions that are measurable by RECIST v1.1 criteria. In patients with mixed histology tumors, the predominant feature must be adenocarcinoma.
• 4. Eastern Cooperative Oncology Group Performance status of 0-2.
• 5. Previous surgery, adjuvant chemotherapy and/or radiation therapy will be allowed, provided radiation therapy is completed at least 2 weeks prior to signing consent and adjuvant therapy was administered more than 6 months prior to signing consent.
• 6. Patients must have bone marrow and organ function as defined below:
• * Absolute Neutrophil Count ≥ 1,500/μL
• * Platelets ≥ 100,000/μL
• * Total Bilirubin ≤2 X ULN
• * AST(SGOT)/ALT(SGPT)/
• * Creatinine ≤2.0 mg/dL And
• * eGFR (using Cockcroft Gault equation) \> 40ml/min
• 7. Patients must be fluent in English and must be able and willing to undergo Comprehensive Geriatric Assessment
• 8. Chemotherapy is harmful to the human fetus. For this reason, sexually active males with partners of childbearing potential must agree to use an accepted and effective method of contraception prior to study entry and for the duration of the study.
• 9. Patients must demonstrate ability to understand and the willingness to sign a written informed consent document.
• 10. Men and women, regardless of race, ethnic group or sexual orientation are eligible for this study.
• 1. Endocrine or acinar pancreatic carcinoma
• * \>2 falls in the past month
• * BMI \<18